▶ 調査レポート

世界の医療用医薬品開発&製造受託機関市場(~2027):サービス別、エンドユーザー別、地域別

• 英文タイトル:Healthcare Contract Development & Manufacturing Organization Market Research Report by Services, End-User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

360iResearchが調査・発行した産業分析レポートです。世界の医療用医薬品開発&製造受託機関市場(~2027):サービス別、エンドユーザー別、地域別 / Healthcare Contract Development & Manufacturing Organization Market Research Report by Services, End-User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19 / MRC2302A032P資料のイメージです。• レポートコード:MRC2302A032P
• 出版社/出版日:360iResearch / 2023年2月1日
• レポート形態:英語、PDF、253ページ
• 納品方法:Eメール(受注後3日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User(1名利用、印刷可)¥742,350 (USD4,949)▷ お問い合わせ
  Enterprise License(企業利用、印刷可)¥1,492,350 (USD9,949)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
360iResearch社発行の当調査レポートでは、2021年に2477.8億ドルであった世界の医療用医薬品開発&製造受託機関市場規模が、2022年に2801.7億ドルに達し、2027年には5226.8億ドルまで年平均13.24%で成長すると予測しています。当レポートは、医療用医薬品開発&製造受託機関の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、サービス別(臨床、受託開発、受託製造、検査サービス)分析、エンドユーザー別(大手製薬企業、後発医薬品企業、中小製薬企業)分析、地域別(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)分析、競争状況など、以下の構成でまとめております。なお、当書には、Catalent Inc.、Covance Inc.、Flex、IQVIA Holdings Inc.、Jabil、Lonza Group Ltd.、Recipharm AB、Sanmina Corporation、Siegfried Holding AG、Thermo Fisher Scientific Inc.などの企業情報が含まれています。
・序論
・調査方法
・エグゼクティブサマリー
・市場概要
・市場インサイト

・世界の医療用医薬品開発&製造受託機関市場規模:サービス別
- 臨床サービスの市場規模
- 受託開発サービスの市場規模
- 受託製造サービスの市場規模
- 検査サービスの市場規模

・世界の医療用医薬品開発&製造受託機関市場規模:エンドユーザー別
- 大手製薬企業における市場規模
- 後発医薬品企業における市場規模
- 中小製薬企業における市場規模

・世界の医療用医薬品開発&製造受託機関市場規模:地域別
- 南北アメリカの医療用医薬品開発&製造受託機関市場規模
アメリカの医療用医薬品開発&製造受託機関市場規模
カナダの医療用医薬品開発&製造受託機関市場規模
ブラジルの医療用医薬品開発&製造受託機関市場規模
...
- アジア太平洋の医療用医薬品開発&製造受託機関市場規模
日本の医療用医薬品開発&製造受託機関市場規模
中国の医療用医薬品開発&製造受託機関市場規模
インドの医療用医薬品開発&製造受託機関市場規模
韓国の医療用医薬品開発&製造受託機関市場規模
台湾の医療用医薬品開発&製造受託機関市場規模
...
- ヨーロッパ/中東/アフリカの医療用医薬品開発&製造受託機関市場規模
イギリスの医療用医薬品開発&製造受託機関市場規模
ドイツの医療用医薬品開発&製造受託機関市場規模
インドの医療用医薬品開発&製造受託機関市場規模
フランスの医療用医薬品開発&製造受託機関市場規模
ロシアの医療用医薬品開発&製造受託機関市場規模
...
- その他地域の医療用医薬品開発&製造受託機関市場規模

・競争状況
・企業情報

The Global Healthcare Contract Development & Manufacturing Organization Market size was estimated at USD 247.78 billion in 2021 and expected to reach USD 280.17 billion in 2022, and is projected to grow at a CAGR 13.24% to reach USD 522.68 billion by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Healthcare Contract Development & Manufacturing Organization to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Services, the market was studied across Clinical, Contract Development, Contract Manufacturing, and Laboratory Services. The Clinical is further studied across Phase I, Phase II, Phase III, and Phase IV. The Contract Development is further studied across Preclinical. The Preclinical is further studied across Bioanalysis and DMPK studies and Toxicology Testing. The Contract Manufacturing is further studied across API/Bulk Drugs, Finished Dose Formulations, and Medical Device. The Medical Device is further studied across Class I, Class II, and Class III. The Laboratory Services is further studied across Analytical Services and Bioanalytical Services.

Based on End-User, the market was studied across Big Pharmaceutical Companies, Generic Pharmaceutical Companies, and Small & Medium-Sized Pharmaceutical Companies.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Healthcare Contract Development & Manufacturing Organization market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Healthcare Contract Development & Manufacturing Organization Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Healthcare Contract Development & Manufacturing Organization Market, including Catalent Inc., Covance Inc., Flex, IQVIA Holdings Inc., Jabil, Lonza Group Ltd., Recipharm AB, Sanmina Corporation, Siegfried Holding AG, and Thermo Fisher Scientific Inc..

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Healthcare Contract Development & Manufacturing Organization Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Healthcare Contract Development & Manufacturing Organization Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Healthcare Contract Development & Manufacturing Organization Market?
4. What is the competitive strategic window for opportunities in the Global Healthcare Contract Development & Manufacturing Organization Market?
5. What are the technology trends and regulatory frameworks in the Global Healthcare Contract Development & Manufacturing Organization Market?
6. What is the market share of the leading vendors in the Global Healthcare Contract Development & Manufacturing Organization Market?
7. What modes and strategic moves are considered suitable for entering the Global Healthcare Contract Development & Manufacturing Organization Market?

レポート目次

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing outsourcing services by pharmaceutical companies
5.1.1.2. Patent expiry and increasing demand for generic drugs
5.1.1.3. Increasing demand for one-stop-shop contract development & manufacturing organization
5.1.2. Restraints
5.1.2.1. Compliance issues while outsourcing and regulatory and legal compliance
5.1.3. Opportunities
5.1.3.1. Increasing investment in pharmaceutical research & development
5.1.3.2. Increasing demand for biological therapies
5.1.4. Challenges
5.1.4.1. Capacity utilization issues affecting the profitability of contract development & manufacturing organization
5.2. Cumulative Impact of COVID-19

6. Healthcare Contract Development & Manufacturing Organization Market, by Services
6.1. Introduction
6.2. Clinical
6.3.1. Phase I
6.3.2. Phase II
6.3.3. Phase III
6.3.4. Phase IV
6.3. Contract Development
6.4.1. Preclinical
6.4.2.1. Bioanalysis and DMPK studies
6.4.2.2. Toxicology Testing
6.4. Contract Manufacturing
6.5.1. API/Bulk Drugs
6.5.2. Finished Dose Formulations
6.5.3. Medical Device
6.5.4.1. Class I
6.5.4.2. Class II
6.5.4.3. Class III
6.5. Laboratory Services
6.6.1. Analytical Services
6.6.2. Bioanalytical Services

7. Healthcare Contract Development & Manufacturing Organization Market, by End-User
7.1. Introduction
7.2. Big Pharmaceutical Companies
7.3. Generic Pharmaceutical Companies
7.4. Small & Medium-Sized Pharmaceutical Companies

8. Americas Healthcare Contract Development & Manufacturing Organization Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Healthcare Contract Development & Manufacturing Organization Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Healthcare Contract Development & Manufacturing Organization Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis, By Key Player
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. Catalent Inc.
12.1.1. Business Overview
12.1.2. Key Executives
12.1.3. Product & Services
12.2. Covance Inc.
12.2.1. Business Overview
12.2.2. Key Executives
12.2.3. Product & Services
12.3. Flex
12.3.1. Business Overview
12.3.2. Key Executives
12.3.3. Product & Services
12.4. IQVIA Holdings Inc.
12.4.1. Business Overview
12.4.2. Key Executives
12.4.3. Product & Services
12.5. Jabil
12.5.1. Business Overview
12.5.2. Key Executives
12.5.3. Product & Services
12.6. Lonza Group Ltd.
12.6.1. Business Overview
12.6.2. Key Executives
12.6.3. Product & Services
12.7. Recipharm AB
12.7.1. Business Overview
12.7.2. Key Executives
12.7.3. Product & Services
12.8. Sanmina Corporation
12.8.1. Business Overview
12.8.2. Key Executives
12.8.3. Product & Services
12.9. Siegfried Holding AG
12.9.1. Business Overview
12.9.2. Key Executives
12.9.3. Product & Services
12.10. Thermo Fisher Scientific Inc.
12.10.1. Business Overview
12.10.2. Key Executives
12.10.3. Product & Services

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing